deferasirox has been researched along with deferoxamine in 206 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (deferoxamine) | Trials (deferoxamine) | Recent Studies (post-2010) (deferoxamine) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 6,703 | 240 | 1,266 |
| Protein | Taxonomy | deferasirox (IC50) | deferoxamine (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 4A | Homo sapiens (human) | 3.275 | |
| Deoxyhypusine hydroxylase | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 58 (28.16) | 29.6817 |
| 2010's | 127 (61.65) | 24.3611 |
| 2020's | 21 (10.19) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Codd, R; Groebler, LK; Kalinowski, DS; Liu, J; Obando, D; Richardson, DR; Schipanski, LG; Witting, PK | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davidoff, AM; Rankovic, Z; Wang, Y; Wu, Q; Yang, J; Young, B | 1 |
| Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G; Nick, HP | 1 |
| Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R | 1 |
| Gordeuk, VR; Goudeau, C; Kassim, OO; Loyevsky, M; Nick, H | 1 |
| Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC | 1 |
| Kontoghiorghes, GJ | 6 |
| Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
| Cappellini, MD | 1 |
| Porter, JB | 2 |
| Hershko, C | 2 |
| Cabantchik, ZI; El, RB; Glickstein, H; Shvartsman, M | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Kolnagou, A; Kontoghiorghes, GJ | 2 |
| Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Fischer, R; Harmatz, P; Nielsen, P; Piga, A | 1 |
| Agaoglu, L; Alberti, D; Athanassiou-Metaxa, M; Aydinok, Y; Bejaoui, M; Cappellini, MD; Capra, M; Coates, T; Cohen, A; Drelichman, G; Fattoum, S; Galanello, R; Giardina, P; Janka-Schaub, G; Kattamis, A; Kilinc, Y; Kourakli-Symeonidis, A; Magnano, C; Marks, P; Olivieri, N; Opitz, H; Perrotta, S; Piga, A; Porter, J; Ressayre-Djaffer, C; Thuret, I; Verissimo, M; Vermylen, C | 1 |
| Greenberg, PL | 1 |
| Niederau, C | 1 |
| Neufeld, EJ | 1 |
| Alberti, D; Bordone, E; Cappellini, MD; Donato, G; Ford, JM; Forni, GL; Galanello, R; Hewson, N; Lavagetto, A; Opitz, H; Origa, R; Piga, A; Sechaud, R; Zanaboni, L; Zappu, A | 1 |
| Arcasoy, MO; Martin, MG | 1 |
| Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F | 1 |
| Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K | 1 |
| Barton, JC | 1 |
| Stumpf, JL | 1 |
| Maggio, A | 1 |
| Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N | 1 |
| Choudhry, VP; Naithani, R | 1 |
| Bernhardt, PV | 1 |
| Cohen, AR; Glimm, E; Porter, JB | 1 |
| Berdoukas, V; Modell, B | 1 |
| Bring, P; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Suzuki, T | 2 |
| Kwiatkowski, JL | 1 |
| Abetz, L; Baladi, JF; Coates, T; Coïc, L; Files, B; Fischer, R; Forni, GL; Lane, P; Marks, P; Mueller, BU; Onyekwere, O; Pakbaz, Z; Porter, J; Rofail, D; Swerdlow, P; Vichinsky, E | 1 |
| Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S | 1 |
| Akehurst, R; Jewitt, K; Karnon, J; Ossa, D; Oyee, J; Tolley, K | 1 |
| Alberti, D; Coates, T; Evans, P; Giardina, PJ; Harmatz, P; Holland, J; Kwiatkowski, JL; Macklin, EA; Neufeld, EJ; Olivieri, N; Porter, J; Vichinsky, E; Walter, PB | 1 |
| Bennett, W; Coppo, R; Hirschberg, R; Ponticelli, C; Scheinman, J | 1 |
| Aguilar, M; Moats, R; Nelson, MD; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Mahmoud, A; Musallam, KM; Taher, AT | 1 |
| Cappellini, MD; Taher, A | 1 |
| Edwards, J; Ibrahim, AS; Spellberg, B | 1 |
| Brewer, C; Gonzalez, I; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP | 1 |
| Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
| Moreau-Marquis, S; O'Toole, GA; Stanton, BA | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A | 1 |
| Kim, DM; Neupane, GP | 1 |
| Cappellini, MD; Pattoneri, P | 1 |
| Ozawa, K | 1 |
| Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A | 1 |
| Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH | 1 |
| Chan, GC; Chan, S; Ha, SY; Ho, PL | 1 |
| Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y | 1 |
| Fibach, E; Prus, E | 1 |
| Telfer, P | 1 |
| Liu, G; Men, P; Perry, G; Smith, MA | 1 |
| Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V | 1 |
| Huang, XP; Spino, M; Templeton, DM; Thiessen, JJ | 1 |
| Fausel, CA | 1 |
| Jetsrisuparb, A; Jetsrisuparb, C; Komvilaisak, P; Wiangnon, S | 1 |
| Balocco, M; Carrara, P; Forni, GL; Pinto, V | 1 |
| Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A | 1 |
| Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G | 1 |
| Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
| Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K | 1 |
| Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G | 1 |
| Porter, JB; Shah, FT | 1 |
| Buchbinder, D; Hsieh, L; Nugent, D; Puthenveetil, G; Soni, A; Stites, J; Vu, D | 1 |
| Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS | 1 |
| Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C | 1 |
| Brittenham, GM | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Mullié, C; Sonnet, P | 1 |
| Berdoukas, V; Coates, T; Farmaki, K; Wood, JC | 1 |
| Chao, NJ; Kanda, J; Kawabata, H | 1 |
| Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R | 1 |
| Corral, M; Duh, MS; Guo, A; Jordan, LB; Sengupta, A; Vekeman, F | 1 |
| Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P | 1 |
| Agaoglu, L; Aydinok, Y; Bejaoui, M; Canatan, D; Cappellini, MD; Capra, M; Clark, J; Cohen, A; Dong, V; Drelichman, G; Economou, M; Fattoum, S; Griffel, L; Kattamis, A; Kilinc, Y; Perrotta, S; Piga, A; Porter, JB | 1 |
| Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J | 1 |
| El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
| Al-awar, R; Alizadeh, S; Aman, A; Attisano, L; Bao, RY; Chau, A; Christova, T; Gronda, M; Hogge, DE; Hurren, R; Isaac, M; Jitkova, Y; Joseph, B; Kasper, J; Miller, BW; Perusini, S; Schimmer, AD; Song, S; Subramaniam, R; Weir, SJ; Wrana, JL | 1 |
| Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M; Saljooghi, AS | 1 |
| Pankaew, T; Torcharus, K | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G | 1 |
| Fernandes, JL | 1 |
| Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E | 1 |
| Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ | 1 |
| Gaur, A | 1 |
| Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L | 1 |
| Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
| Brown, GC; Patton, WN; St Pierre, TG; Tapp, HE; Taylor, DJ | 1 |
| Dessi, C; Galanello, R; Giardina, PJ; Grady, RW; Kleinert, DA; Randolph, RE | 1 |
| Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
| Armstrong, EP; Ballas, SK; Sasane, M; Skrepnek, GH; Snodgrass, SM | 1 |
| Chandiwana, D; Karnon, J; Tolley, K; Vieira, J | 1 |
| Alderson, D; Bedford, M; Chadwick, C; Ford, SJ; Iqbal, TH; Jansson, PJ; Kalinowski, DS; Lovejoy, DB; Lui, GY; Nichols, L; Obeidy, P; Richardson, DR; Tselepis, C; Tucker, O | 1 |
| Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E | 1 |
| Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H | 1 |
| Ruivard, M | 1 |
| Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S | 1 |
| Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A | 1 |
| Kurtoglu, E; Uygun, V | 1 |
| Kim, C; Kim, SW; Lee, HS; Lee, JY; Moon, JH | 1 |
| Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, DH | 1 |
| Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL | 1 |
| Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G | 1 |
| Brittenham, GM; Olivieri, NF | 1 |
| Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C | 1 |
| Ammirabile, M; Casale, M; Cinque, P; Costantini, S; Di Matola, T; Filosa, A; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ | 1 |
| Babaie, M; Mendi, FD; Saljooghi, AS; Saljooghi, ZS; Zahmati, M | 1 |
| Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R | 1 |
| Haghpanah, S; Karimi, M; Zahedi, Z; Zarei, T | 1 |
| Huang, L; Jiang, H; Xia, S; Zhang, W | 1 |
| Aydinok, Y; Belhoul, KM; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, Y; Lawniczek, T; Pennell, DJ; Piga, A; Porter, JB; Weisskopf, M; Yesilipek, A; Zhang, Y | 1 |
| Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA | 1 |
| Coates, TD | 1 |
| Merkel, DG; Nagler, A | 1 |
| Cappellini, MD; Cassinerio, E; Duca, L; Fraquelli, M; Orofino, N; Poggiali, E; Roghi, A; Zanaboni, L | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY | 1 |
| Bhatia, R; Donohue, C; Forman, SJ; Krishnan, A; Meng, Z; Pullarkat, V; Synold, TW; Tomassetti, S; Yamamoto, VN | 1 |
| Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V | 1 |
| Alfonso, P; Andrade-Campos, M; Andreu, V; Gervas-Arruga, J; Giraldo, P; Irun, P; Medrano-Engay, B; Pocovi, M | 1 |
| Heath, JL; Lavau, CP; Wechsler, DS; Weiss, JM | 1 |
| Banerjee, A; Bentley, M; Bird, R; Forsyth, C; Grigg, A; Grigoriadis, G; Kellner, S; Mifsud, NA; Motum, P; Opat, S; Szer, J; Tam, C | 1 |
| Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, YR; Musallam, KM; Pennell, DJ; Piga, A; Porter, JB; Shen, J; Yesilipek, A | 1 |
| Aaseth, J; Andersen, O; Cao, Y; Skaug, MA | 1 |
| Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z | 1 |
| Haghpanah, S; Karimi, M | 1 |
| Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y | 1 |
| Choi, SE; Han, SJ; Jung, IR; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, SA | 1 |
| Arandi, N; Ashrafi, A; Eatemadfar, P; Haghpanah, S; Karimi, M; Radwan, AH; Safaei, S; Taher, AT; Zahedi, Z; Zarei, T | 1 |
| Aydinok, Y; Cappellini, MD; Constantinovici, N; El-Beshlawy, A; Elalfy, M; Habr, D; Karakas, Z; Kattamis, A; Kilinç, Y; Origa, R; Perrotta, S; Porter, JB; Shen, J; Viprakasit, V | 1 |
| Garbowski, M; Porter, J; Vlachodimitropoulou Koumoutsea, E | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA | 1 |
| Chen, V; Clemons, KV; Cohen, K; Ferreira, JA; Haagensen, JA; Hsu, JL; Martinez, M; Nazik, H; Penner, JC; Spormann, AM; Stevens, DA | 1 |
| El Rassi, F; Saliba, AN; Taher, AT | 1 |
| Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD | 1 |
| Jeong, YA; Joung, SY; Kang, S; Kim, BR; Kim, JL; Lee, DH; Lee, SI; Lee, SY; Min, BW; Na, YJ; Oh, SC | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E | 1 |
| Kontoghiorghe, CN; Kontoghiorghes, GJ | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Chattipakorn, N; Chattipakorn, SC; Krintratun, W; Sripetchwandee, J; Wongjaikam, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Deghedy, MR; Ebeid, WM; El-Shazly, AA; Elkitkat, RS | 1 |
| Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Della Pepa, R; Pane, F; Picardi, M; Pugliese, N | 1 |
| Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A | 1 |
| Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Antonucci, R; Asara, MA; Caggiari, S; Capobianco, G; Dessole, S; Dore, F; Fozza, C; Monti, A; Vacca, N; Zaccheddu, F | 1 |
| Leitch, HA; Wong, SA | 1 |
| Gattermann, N | 1 |
| Sivaramakrishnan, G; Sridharan, K | 1 |
| Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
| Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y | 1 |
| Lee, JA; Tchantchaleishvili, V; Vidula, H | 1 |
| Sari, TT; Wahidiyat, PA; Yosia, M | 1 |
| Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A | 1 |
| Chen, G; Dou, H; Qin, Y; Zhao, Y | 1 |
| Abu Shosha, GM | 1 |
| Bagheri, B; Eghbali, A; Khalilpour, A; Taherahmadi, H | 1 |
| Chen, X; Hsieh, YW; Lin, CH; Peng, CT; Song, TS; Weng, TF; Wu, CC; Wu, KH | 1 |
| Afzal, RR; Bagheri, B; Eghbali, A; Shokri, P | 1 |
| Chayakulkeeree, M; Pati, N; Tangkoskul, T; Thamlikitkul, V; Tiengrim, S; Waywa, D | 1 |
| Ghaffari Darab, M; Khorasani, E; Photogeraphy, H; Saiyarsarai, P; Seyedifar, M | 1 |
| Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG | 1 |
| Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V | 1 |
| Amano, R; Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Shibutani, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S | 1 |
| Chhabra, IK; Ibrahim, HM; Mohammed, NS; Shafie, AA; Wong, JHY | 1 |
| Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ | 1 |
| Lv, H; Shang, P; Wang, S; Xue, Y; Zhang, G; Zhou, L; Zhou, S | 1 |
| Azulay, Y; Colodner, R; Dujovny, T; Halevy, R; Koren, A; Levin, C; Swartz, N; Tanous, O | 1 |
| Cheng, K; Greenway, A; Kaplan, Z; Wu, S; Zargari, A | 1 |
| Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S | 1 |
| Baum, L; Ho, A; Kwan, P | 1 |
| Applová, L; Franz, KJ; Hašková, P; Homola, P; Jansová, H; Roh, J; Šimůnek, T; Vávrová, K | 1 |
| Argenziano, M; Di Paola, A; Marrapodi, MM; Rossi, F; Tortora, C | 1 |
| Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Qadah, T | 1 |
| Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
| Badawy, SM; Shah, A; Shah, R | 1 |
| Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y | 1 |
| Aydinok, Y | 1 |
59 review(s) available for deferasirox and deferoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent Advances with KDM4 Inhibitors and Potential Applications.
Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neoplasms | 2022 |
Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2005 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Compliance; Siderophores; Transfusion Reaction; Triazoles | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Current status of iron overload and chelation with deferasirox.
Topics: Benzoates; beta-Thalassemia; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles | 2007 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles | 2008 |
[Iron overload and iron chelation therapy in transfusion-dependent patients].
Topics: Benzoates; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Triazoles | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles | 2008 |
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Triazoles | 2008 |
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles | 2008 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2009 |
[Pathogenesis of transfusional iron overload and iron chelation therapy].
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Drug Design; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Transferrin; Triazoles | 2009 |
Update on survival in thalassemia major.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles | 2009 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles | 2010 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2010 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Practice Guidelines as Topic; Triazoles | 2011 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles | 2011 |
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function | 2011 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2012 |
[Iron overload and iron chelation therapy].
Topics: Benzoates; Deferasirox; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2012 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles | 2013 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles | 2013 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
Chelation in metal intoxication--Principles and paradigms.
Topics: Administration, Oral; Antidotes; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Heavy Metal Poisoning; Humans; Penicillamine; Poisoning; Pyridones; Succimer; Triazoles; Trientine; Unithiol | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles | 2016 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2017 |
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles | 2018 |
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Topics: Databases, Factual; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Odds Ratio; Thalassemia | 2019 |
Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran.
Topics: beta-Thalassemia; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Humans; Iran; Iron Chelating Agents; Tablets | 2020 |
Emerging Roles of the Iron Chelators in Inflammation.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agents; Iron Overload; Mammals; Pyridones | 2022 |
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles | 2022 |
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles | 2023 |
25 trial(s) available for deferasirox and deferoxamine
| Article | Year |
|---|---|
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Intestinal Absorption; Iron; Iron Overload; Male; Triazoles | 2003 |
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Liver; Male; Middle Aged; Safety; Triazoles | 2006 |
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles | 2006 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Headache; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Respiratory Tract Infections; Treatment Outcome; Triazoles | 2007 |
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Siderophores; Triazoles | 2006 |
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Topics: Adolescent; Adult; Antidotes; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles | 2007 |
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Splenectomy; Triazoles | 2008 |
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires; Transfusion Reaction; Treatment Outcome; Triazoles | 2008 |
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
Topics: Adolescent; Adult; Ascorbic Acid; Benzoates; beta-Thalassemia; C-Reactive Protein; Child; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Lipid Peroxidation; Male; Oxidants; Oxidative Stress; Triazoles; Vitamin E | 2008 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult | 2009 |
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Deferoxamine; Female; Follow-Up Studies; Growth and Development; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Triazoles; Young Adult | 2011 |
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway | 2011 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult | 2012 |
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Triazoles | 2013 |
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Pilot Projects; Thalassemia; Transferrin; Triazoles; Young Adult | 2013 |
The effects of chelators on zinc levels in patients with thalassemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Female; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Medication Adherence; Myocardium; Treatment Outcome; Triazoles; Troponin T; Young Adult | 2014 |
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Prospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles | 2015 |
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Siderophores; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iran; Iron Chelating Agents; Liver; Male; Middle Aged; Myocardium; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Time Factors; Young Adult | 2019 |
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Topics: Administration, Oral; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pilot Projects; Young Adult | 2019 |
A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Deferasirox; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Overload; Male; Time Factors | 2019 |
122 other study(ies) available for deferasirox and deferoxamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Chelating Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deferoxamine; Dogs; Ferric Compounds; Humans; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Iron Overload; Kidney; Models, Molecular; Molecular Structure; Neuroectodermal Tumors, Primitive, Peripheral; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Transferrin | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Erythrocyte Transfusion; Erythrocytes, Abnormal; Feces; Female; Ferritins; Heart; Hepatocytes; Hot Temperature; Injections, Intravenous; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Liver; Mice; Molecular Structure; Mononuclear Phagocyte System; Myocardium; Organ Specificity; Rats; Rats, Wistar; Tissue Distribution; Transfusion Reaction; Triazoles; Urine | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles | 2001 |
Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.
Topics: Analysis of Variance; Animals; Antimalarials; Benzoates; Cells, Cultured; Chelating Agents; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Erythrocytes; Hypoxanthine; Plasmodium falciparum; Triazoles | 2001 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2003 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
Topics: Animals; Benzoates; Catalysis; Cell Line; Cell Survival; Cells; Cytosol; Deferasirox; Deferiprone; Deferoxamine; Endosomes; Humans; Iron; Iron Chelating Agents; Mice; Microscopy, Fluorescence; Mitochondria; Pyridones; Time Factors; Triazoles | 2005 |
[Clinical findings and therapy of classical hereditary haemochromatosis (type 1)].
Topics: Benzoates; Deferasirox; Deferoxamine; Ferritins; Genes, MHC Class I; Genes, Recessive; Hemochromatosis; Humans; Phlebotomy; Point Mutation; Prognosis; Siderophores; Triazoles | 2005 |
Deferasirox versus deferoxamine.
Topics: Benzoates; Data Interpretation, Statistical; Deferasirox; Deferoxamine; Humans; Patient Compliance; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles | 2008 |
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Topics: Adult; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Female; Humans; Interviews as Topic; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Siderophores; State Medicine; Triazoles; United Kingdom | 2008 |
Acute kidney injury due to deferoxamine in a renal transplant patient.
Topics: Acute Kidney Injury; Benzoates; Creatinine; Deferasirox; Deferoxamine; Humans; Kidney Transplantation; Siderophores; Triazoles | 2008 |
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Gerbillinae; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Siderophores; Tissue Distribution; Triazoles | 2008 |
Iron and hepatitis C: what can we learn from thalassemia major?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Female; Ferritins; Hepacivirus; Hepatitis C, Chronic; Humans; Iron; Iron Deficiencies; Male; Phlebotomy; Siderophores; Triazoles | 2008 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gerbillinae; Heart; Iron Overload; Liver; Organ Size; Treatment Outcome; Triazoles | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure | 2008 |
Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
Topics: Anti-Bacterial Agents; Benzoates; Biofilms; Cells, Cultured; Conalbumin; Cystic Fibrosis; Deferasirox; Deferoxamine; Epithelial Cells; Humans; Iron Chelating Agents; Pseudomonas Infections; Tobramycin; Triazoles; United States; United States Food and Drug Administration | 2009 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus | 2009 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Triazoles | 2010 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles | 2010 |
Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
Topics: Aged; Alzheimer Disease; Benzoates; Blood-Brain Barrier; Brain; Chelation Therapy; Deferasirox; Deferoxamine; Drug Carriers; Ferritins; Humans; Iron; Iron Chelating Agents; Metals; Molecular Structure; Nanoparticles; Triazoles | 2010 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult | 2010 |
Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Topics: Adenosine Triphosphate; Animals; Benzoates; Biological Transport; Cell Line; Cell Polarity; Deferasirox; Deferoxamine; Dogs; Epithelial Cells; Exocytosis; Iron; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Kidney; Models, Biological; Pyridones; Siderophores; Temperature; Triazoles | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Siderophores; Survival Rate; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Siderophores; State Medicine; Survival Analysis; Triazoles; United Kingdom | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult | 2011 |
Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Topics: Anemia, Dyserythropoietic, Congenital; Benzoates; Bone Marrow Transplantation; Child, Preschool; Deferasirox; Deferoxamine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Unrelated Donors | 2012 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles | 2010 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles | 2011 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |
In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
Topics: Antimalarials; Benzoates; Chloroquine; Deferasirox; Deferiprone; Deferoxamine; Glutathione; Hemeproteins; Hemin; Hydrogen Peroxide; Inhibitory Concentration 50; Iron Chelating Agents; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid | 2011 |
Iron chelation in thalassemia: time to reconsider our comfort zones.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles | 2011 |
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
Topics: Adolescent; Adult; Age Factors; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Medical Records; Medication Adherence; Middle Aged; North America; Retrospective Studies; Self Report; Thalassemia; Triazoles; United Kingdom; Young Adult | 2011 |
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Cohort Studies; Deferasirox; Deferoxamine; Female; Florida; Hospitalization; Humans; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Middle Aged; Missouri; New Jersey; Retrospective Studies; Triazoles; United States; Young Adult | 2012 |
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats.
Topics: Animals; Benzoates; Body Weight; Cadmium; Chelating Agents; Chelation Therapy; Deferasirox; Deferoxamine; Iron; Male; Rats; Rats, Wistar; Tissue Distribution; Triazoles | 2012 |
Health-related quality of life in Thai thalassemic children treated with iron chelation.
Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles | 2011 |
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult | 2012 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Myocardium; Thalassemia; Triazoles; Ventricular Function, Left | 2012 |
Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
Topics: Adolescent; Adult; Aged; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Hematologic Diseases; Hemosiderosis; Humans; Infant; Infusions, Intravenous; Injections, Subcutaneous; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Retrospective Studies; ROC Curve; Sensitivity and Specificity; South Australia; Triazoles | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Deferoxamine; Drug Utilization; Female; Health Expenditures; Humans; Insurance Claim Review; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Patient Preference; Proportional Hazards Models; Racial Groups; Retrospective Studies; Sex Factors; Triazoles; United States | 2013 |
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Drug Costs; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Overload; Medication Adherence; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Triazoles; United Kingdom | 2012 |
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deferasirox; Deferoxamine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Female; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred BALB C; Mice, Nude; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Studies; Deferasirox; Deferoxamine; Drug Costs; Female; Humans; Infusions, Intravenous; Iran; Iron Chelating Agents; Iron Overload; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult | 2013 |
Iron-chelation therapy with oral chelators in patients with thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult | 2013 |
Antibacterial and antibiofilm effects of iron chelators against Prevotella intermedia.
Topics: Anti-Bacterial Agents; Bacterial Load; Benzoates; Biofilms; Chelating Agents; Deferasirox; Deferoxamine; Iron; Metronidazole; Microbial Sensitivity Tests; Microbial Viability; Prevotella intermedia; Triazoles | 2013 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles | 2013 |
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Chlorides; Crosses, Genetic; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fas Receptor; Female; Ferric Compounds; Gene Expression Regulation, Leukemic; Iron; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Leukemia L1210; Liver; Lymphoma, T-Cell; Mice; Mice, Inbred Strains; Neoplasm Proteins; Triazoles; Tumor Burden | 2013 |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles | 2013 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Susceptibility; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Iron Chelating Agents; Iron Overload; Italy; Kidney; Male; Nephrolithiasis; Retrospective Studies; Transfusion Reaction; Triazoles; Ultrasonography | 2014 |
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Triazoles | 2014 |
Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Topics: Animals; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Iron; Iron Chelating Agents; Male; Rats; Rats, Wistar; Spectrophotometry, Atomic; Thallium; Triazoles | 2016 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferoxamine; Female; Humans; Infant; Injections; Iron Chelating Agents; Male; Patient Compliance; Personal Satisfaction; Triazoles; Young Adult | 2014 |
Laboratory investigation of platelet function in patients with thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult | 2014 |
Bad liver and a broken heart.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles | 2014 |
Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overload; Male; Treatment Outcome; Triazoles | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult | 2014 |
Iron chelators induce autophagic cell death in multiple myeloma cells.
Topics: Autophagy; Benzoates; Cell Line, Tumor; Cell Proliferation; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Humans; Iron Chelating Agents; Multiple Myeloma; Primary Cell Culture; Reactive Oxygen Species; Triazoles | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
Topics: Adult; Aged; Benzoates; Biomarkers; Cytokines; Deferasirox; Deferoxamine; Female; Ferritins; Follow-Up Studies; Gaucher Disease; Hepcidins; Hexosaminidases; Homeostasis; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Overload; Macrophage Activation; Macrophages; Male; Middle Aged; Quality of Life; Triazoles | 2014 |
Effects of iron depletion on CALM-AF10 leukemias.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biological Transport; Cell Line, Tumor; Chelation Therapy; Combined Modality Therapy; Deferasirox; Deferoxamine; Fibroblasts; Hematopoietic Stem Cells; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron, Dietary; Leukemia, Experimental; Mice; Mice, Knockout; Monomeric Clathrin Assembly Proteins; Oncogene Proteins, Fusion; Radiation Chimera; Spleen; Triazoles; Tumor Burden | 2014 |
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; Deferoxamine; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Macrophages; Male; Mice; Myelodysplastic Syndromes; NF-kappa B; RNA, Long Noncoding; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha | 2015 |
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress.
Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult | 2015 |
The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Ferritins; Health Status; Hemophilia A; Humans; Internationality; Iran; Male; Plasma; Surveys and Questionnaires; Thalassemia; Triazoles; Young Adult | 2015 |
Involvement of iron depletion in palmitate-induced lipotoxicity of beta cells.
Topics: Animals; Apoferritins; Benzoates; Cell Death; Cell Line, Tumor; Chlorides; Deferasirox; Deferoxamine; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Ferric Compounds; Ferrous Compounds; Gene Expression Regulation; Humans; Insulin-Secreting Cells; Iron Chelating Agents; Iron Deficiencies; JNK Mitogen-Activated Protein Kinases; Palmitic Acid; Rats; Receptors, Transferrin; Signal Transduction; Transcription Factor CHOP; Transferrin; Triazoles | 2015 |
Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Developing Countries; Drug Therapy, Combination; Female; Ferritins; Humans; Iran; Lebanon; Male; Siderophores; Triazoles | 2015 |
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Topics: Benzoates; Cell Line; Deferasirox; Deferiprone; Deferoxamine; Drug Synergism; Humans; Intracellular Space; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2015 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles | 2015 |
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzoates; Biofilms; Chlorides; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Plankton; Pyridones; Spores, Fungal; Tetrazolium Salts; Triazoles | 2015 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult | 2015 |
Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Topics: Apoptosis; Benzoates; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deferasirox; Deferoxamine; Endoplasmic Reticulum Stress; Humans; Iron Chelating Agents; JNK Mitogen-Activated Protein Kinases; Microscopy, Confocal; Neoplasm Staging; Prognosis; Reactive Oxygen Species; Siderophores; Signal Transduction; Stomach Neoplasms; Triazoles; Tumor Cells, Cultured | 2016 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasirox; Deferoxamine; Dendrites; Diet; Disease Models, Animal; Drug Therapy, Combination; Iron; Iron Chelating Agents; Iron Overload; Male; Mitochondrial Dynamics; Neurodegenerative Diseases; Phosphorylation; Random Allocation; Rats, Wistar; tau Proteins; Triazoles | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA.
Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Eye Diseases; Female; Humans; Iron Chelating Agents; Male; Optic Nerve; Retina; Retinal Diseases; Retrospective Studies; Siderophores; Thalassemia; Treatment Outcome; Triazoles; Visual Acuity | 2017 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Myelodysplastic Syndromes | 2018 |
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles | 2017 |
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2018 |
Pregnancy Outcome among Women with Beta-Thalassemia Major in North Sardinia.
Topics: Abortion, Spontaneous; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Diabetes, Gestational; Female; Fetal Growth Retardation; Humans; Iron Chelating Agents; Italy; Pregnancy; Pregnancy Outcome; Premature Birth; Triazoles | 2017 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Female; Iron Chelating Agents; Iron Overload; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Triazoles | 2018 |
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Topics: Adult; Cardiomyopathies; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Extracorporeal Membrane Oxygenation; Female; Hemochromatosis; Humans; Iron Chelating Agents; Shock, Cardiogenic | 2018 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Prospective Studies; Treatment Outcome | 2018 |
Beliefs and Adherence Associated With Oral and Infusion Chelation Therapies in Jordanian Children and Adolescents With Thalassemia Major: A Comparative Study.
Topics: Adolescent; beta-Thalassemia; Chelation Therapy; Child; Cross-Sectional Studies; Culture; Deferasirox; Deferoxamine; Female; Humans; Jordan; Male; Medication Adherence; Surveys and Questionnaires | 2019 |
Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Deferasirox; Deferoxamine; Drug Synergism; Fungal Capsules; Gene Expression Regulation, Fungal; Humans; Invasive Fungal Infections; Iron; Iron Chelating Agents; Iron Overload; Metabolic Networks and Pathways; Microbial Sensitivity Tests; Virulence Factors | 2020 |
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Transfusion Reaction; Treatment Outcome; Young Adult | 2020 |
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles | 2021 |
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Topics: Animals; Antigens, CD; B7-H1 Antigen; Cadherins; Cell Cycle; Cell Line, Tumor; Deferasirox; Deferoxamine; Epithelial-Mesenchymal Transition; Female; Furans; Humans; Iron; Iron Chelating Agents; Iron Deficiencies; Ketones; Mice; Mice, Inbred BALB C; Mice, Nude; RNA, Messenger; RNA, Neoplasm; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.
Topics: Benzoates; Blood Transfusion; Cost of Illness; Cross-Sectional Studies; Deferasirox; Deferoxamine; Humans; Malaysia; Quality of Life; Thalassemia; Triazoles | 2021 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc | 2021 |
Iron Chelator Induces Apoptosis in Osteosarcoma Cells by Disrupting Intracellular Iron Homeostasis and Activating the MAPK Pathway.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deferasirox; Deferoxamine; Humans; Iron; MAP Kinase Signaling System; Mice; Osteosarcoma; Siderophores; Xenograft Model Antitumor Assays | 2021 |
Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Kidney; Male; Middle Aged; Retrospective Studies; Young Adult | 2021 |
Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Retrospective Studies; Triazoles | 2022 |
Characterisation of individual ferritin response in patients receiving chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2022 |
Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models.
Topics: Alzheimer Disease; Animals; Deferasirox; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Chelating Agents; Mice; Mice, Transgenic; tau Proteins; Tauopathies | 2022 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Oxidopamine; PC12 Cells; Rats | 2022 |
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia | 2023 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles | 2023 |